Dr. Yoshiko Stowell is Vice President of Regulatory Affairs at Kenai Therapeutics. She has over 20 years of experience in drug development of small molecules primarily for neurology indications including Parkinson’s disease, Alzheimer’s disease, and pain management. She has diverse experience in R&D, Project Management, Clinical Operations, and Regulatory Affairs. Most recently, she was Head of Regulatory Affairs at Neuron23, Inc. where she led the regulatory strategy for the development of a LRRK2 inhibitor for the treatment of Parkinson’s disease in patients identified by in vitro companion diagnostics. Previously, she contributed to the MAA approval of Numient (levodopa/carbidopa extended release capsules), known as Rytary in the US for the treatment of Parkinson’s disease and development of IPX203, a 2nd generation levodopa/carbidopa extended release capsules at Impax Therapeutics, Inc., merged with Amneal Pharma.

Additional roles include Vice President of Regulatory Affairs and Quality Assurance at AmyriAD Therapeutics, Inc and Sr. Director of Regulatory Affairs at Eidos Therapeutics, BridgeBio Pharma. She is currently a Chair of the Regulatory Affairs Professional Society (RAPS) San Francisco Bay Area Chapter.

Dr. Stowell received her Doctor of Philosophy in pharmaceutical science from University of the Pacific, Master of Science in chemical engineering from University of Oklahoma, and Bachelor of Science in pure and applied chemistry from Tokyo University of Science.